Its 360° expertise in molecular diagnostics and genotyping by sequencing is based on three fundamental pillars: (i) proprietary R&D know-how, (ii) in-house manufacturing of tests and (iii) control of distribution channels (directly with laboratories or via recognised partners). With an all-in-one offering, from collection of samples through to analysis and automation of results obtained, ABL DIAGNOSTICS is present at each stage of the value chain. By focusing on sequencing of target pathogens, with a view to optimising disease management, ABL DIAGNOSTICS offers a range of tests which enable the determination of each patient’s ability to respond favourably to a given treatment before administration. The sequencing processes offered by ABL DIAGNOSTICS are the two most popular DNA sequencing methods: so-called Sanger capillary sequencing and High-throughput sequencing or Next-Generation Sequencing (NGS).
PARIS-( BUSINESS WIRE)-Regulatory News:ĪBL DIAGNOSTICS (Euronext Paris, FR001400AHX6, ABLD) today presents its ABLDX 2027 medium-term development plan to the financial community.įormed from the end-August 2022 merger of ABL France into the listed entity without activity ETABLISSEMENTS FAUVET-GIREL (renamed ABL DIAGNOSTICS), the company aims to be part of the Top 3 worldwide players in genotyping of pathogens linked to infectious diseases.Ī strategy based on proprietary expertise in sequencing processes
0 kommentar(er)
